With the market for women’s health-related therapeutics set to grow 30% to $131bn by 2028, according to Evaluate, investors should be flocking to companies focused on conditions that uniquely affect women. While there has been growing public and private investment in recent years, small check sizes and tentative investor commitments remain challenges.
“Women's health is undervalued and underserved and the consequences are dire,” Raysa Bousleiman, senior vice president, life science and healthcare venture capital relationships, Silicon Valley Bank, said during a panel discussion at 2024's Biotech Showcase